Erratum: RNAi‑mediated EZH2 depletion decreases MDR1 expression and sensitizes multidrug‑resistant hepatocellular carcinoma cells to chemotherapy (Oncol rep 29 (2013) (1037‑1042) DOI: 10.3892/or.2013.2222);RNAi-mediated EZH2 depletion decreases MDR1 expression and sensitizes multidrug-resistant hepatocellular carcinoma cells to chemotherapy

Oncology Reports

Volumn 29, Issue 3, 2013, Pages 1037-1042

  Tang, Bo ^a   Zhang, Yi ^a   Liang, Rui ^a   Gao, Zhenming ^a   Sun, Deguang ^a   Wang, Liming ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Enhancer of zeste homologue 2; Hepatocellular carcinoma; Multidrug resistance; SiRNA

Indexed keywords

BETA ACTIN; FLUOROURACIL; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR EZH2;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL SURVIVAL; CHEMOSENSITIZATION; CONTROLLED STUDY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN TARGETING; RNA INTERFERENCE;

EID: 84872782925     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2024.8809     Document Type: Erratum

References (33)

1. Okuda K: Hepatocellular carcinoma. J Hepatol 32 (Suppl 1): 225-237, 2000. (Pubitemid 30123637)
2. Rahbari NN, Mehrabi A, Mollberg NM, et al: Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg 253: 453-469, 2011.
3. Takara K, Sakaeda T and Okumura K: An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr Pharm Des 12: 273-286, 2006.
4. Zhai BJ, Shao ZY, Zhao CL, Hu K and Wu F: Development and characterization of multidrug resistant human hepatocarcinoma cell line in nude mice. World J Gastroenterol 12: 6614-6619, 2006. (Pubitemid 44794937)
5. Warmann S, Gohring G, Teichmann B, Geerlings H, Pietsch T and Fuchs J: P-glycoprotein modulation improves in vitro chemosensitivity in malignant pediatric liver tumors. Anticancer Res 23: 4607-4611, 2003. (Pubitemid 38173874)
6. Li B, Ye T, Zhao L, et al: Effects of multidrug resistance, antisense RNA on the chemosensitivity of hepatocellular carcinoma cells. Hepatobiliary Pancreat Dis Int 5: 552-559, 2006. (Pubitemid 44782095)
7. Merino V, Jimenez-Torres NV and Merino-Sanjuan M: Relevance of multidrug resistance proteins on the clinical efficacy of cancer therapy. Curr Drug Deliv 1: 203-212, 2004.
8. Luqmani YA: Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract 14 (Suppl 1): 35-48, 2005. (Pubitemid 41161048)
9. Cardoso C, Mignon C, Hetet G, Grandchamps B, Fontes M and Colleaux L: The human EZH2 gene: genomic organisation and revised mapping in 7q35 within the critical region for malignant myeloid disorders. Eur J Hum Genet 8: 174-180, 2000. (Pubitemid 30189860)
10. Sewalt RG, van der Vlag J, Gunster MJ, et al: Characterization of interactions between the mammalian polycomb-group proteins Enx1/EZH2 and EED suggests the existence of different mammalian polycomb-group protein complexes. Mol Cell Biol 18: 3586-3595, 1998. (Pubitemid 28240531)
11. Koyanagi M, Baguet A, Martens J, Margueron R, Jenuwein T and Bix M: EZH2 and histone 3 trimethyl lysine 27 associated with Il4 and Il13 gene silencing in Th1 cells. J Biol Chem 280: 31470-31477, 2005. (Pubitemid 41291889)
12. Cao R, Wang L, Wang H, et al: Role of histone H3 lysine 27 meth-ylation in Polycomb-group silencing. Science 298: 1039-1043, 2002. (Pubitemid 35247314)
13. Vire E, Brenner C, Deplus R, et al: The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439: 871-874, 2006. (Pubitemid 43255707)
14. De Haan G and Gerrits A: Epigenetic control of hematopoietic stem cell aging the case of Ezh2. Ann N Y Acad Sci 1106: 233-239, 2007. (Pubitemid 47443044)
15. Caretti G, Di Padova M, Micales B, Lyons GE and Sartorelli V: The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation. Genes Dev 18: 2627-2638, 2004. (Pubitemid 39453102)
16. Varambally S, Dhanasekaran SM, Zhou M, et al: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419: 624-629, 2002.
17. Visser HP, Gunster MJ, Kluin-Nelemans HC, et al: The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br J Haematol 112: 950-958, 2001. (Pubitemid 32322920)
18. Steele JC, Torr EE, Noakes KL, et al: The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens. Br J Cancer 95: 1202-1211, 2006. (Pubitemid 44658484)
19. Sasaki M, Ikeda H, Itatsu K, et al: The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma. Lab Invest 88: 873-882, 2008.
20. Chen Y, Lin MC, Yao H, et al: Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin. Hepatology 46: 200-208, 2007. (Pubitemid 47171937)
21. Hu S, Yu L, Li Z, et al: Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biol Ther 10: 788-795, 2010.
22. Ougolkov AV, Bilim VN and Billadeau DD: Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2. Clin Cancer Res 14: 6790-6796, 2008.
23. Simon JA and Lange CA: Roles of the EZH2 histone methyl-transferase in cancer epigenetics. Mutat Res 647: 21-29, 2008.
24. Stewart ZA, Westfall MD and Pietenpol JA: Cell-cycle dysregu-lation and anticancer therapy. Trends Pharmacol Sci 24: 139-145, 2003.
25. Sudo T, Utsunomiya T, Mimori K, et al: Clinicopathological significance of EZH2 mRNA expression in patients with hepato-cellular carcinoma. Br J Cancer 92: 1754-1758, 2005. (Pubitemid 40756488)
26. Cai MY, Tong ZT, Zheng F, et al: EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies. Gut 60: 967-976, 2011.
27. Grubach L, Juhl-Christensen C, Rethmeier A, et al: Gene expression profiling of Polycomb, Hox and Meis genes in patients with acute myeloid leukaemia. Eur J Haematol 81: 112-122, 2008. (Pubitemid 352022720)
28. Effendi K, Mori T, Komuta M, Masugi Y, Du W and Sakamoto M: Bmi-1 gene is upregulated in early-stage hepa-tocellular carcinoma and correlates with ATP-binding cassette transporter B1 expression. Cancer Sci 101: 666-672, 2010.
29. van Kemenade FJ, Raaphorst FM, Blokzijl T, et al: Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood 97: 3896-3901, 2001.
30. Tan J, Yang X, Zhuang L, et al: Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 21: 1050-1063, 2007. (Pubitemid 46686474)
31. Wu ZL, Zheng SS, Li ZM, Qiao YY, Aau MY and Yu Q: Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression. Cell Death Differ 17: 801-810, 2010.
32. Fussbroich B, Wagener N, Macher-Goeppinger S, et al: EZH2 depletion blocks the proliferation of colon cancer cells. PLoS One 6: e21651, 2011.
33. Hannon GJ: RNA interference. Nature 418: 244-251, 2002. (Pubitemid 34773784)